Dennis F. G. Remst
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dennis F. G. Remst has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Mirjam H. M. Heemskerk
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
28 shared publications - J. H. Frederik Falkenburg
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
26 shared publications - Michel G. D. Kester
Department of Hematology, Leiden University Medical Center
22 shared publications - Anne K. Wouters
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
21 shared publications - Arnoud H. de Ru
Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands
21 shared publications - Dirk M. van der Steen
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
21 shared publications
Latest Publications
- 15 October 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (16) , 1998-2012
Immunoglobulin constant domains as targets for T-cell receptor–based treatment of multiple myeloma
Despite major progress with chimeric antigen receptor T-cell therapy, multiple myeloma (MM) remains largely incurable and most patients relapse. To broaden therapeutic options and overcome antigen escape, we explored T-cell receptor (TCR)–based targeting of intracellular antigens derived from immunoglobulin heavy chain constant domains. Using HLA class-I peptidomics, we identified 9 immunoglobulin G (IgG)– or IgA-derived peptides presented by common HLA alleles (HLA-A∗01:01, HLA-A∗02:01, HLA-A∗03:01, and HLA-B∗07:02). High-avidity T-cell clones recognizing 4 of these epitopes were isolated from HLA-mismatched healthy donors. The transfer of these immunoglobulin-specific TCRs into donor T cells conferred potent and selective recognition of IgG- or IgA-expressing MM cell lines, sparing antigen-negative cells. Safety profiling confirmed strict HLA-restricted specificity without cross-reactivity toward other HLA alleles, non–B-lineage tumor cell lines, or healthy tissues, except for the depletion of isotype-matched B cells. Immunoglobulin-TCR T cells efficiently lysed patient-derived MM cells ex vivo and eradicated established IgA- or IgG-expressing MM tumors in murine xenograft models. Mechanistic studies revealed that dendritic cells could cross-present immunoglobulin peptides at high serum concentrations, potentially enhancing T-cell activation in vivo. Importantly, subtype-specific depletion of B cells implies that immunoglobulin-TCR T-cell therapy could partly preserve humoral immunity, reducing the need for antibody replacement compared with pan–B-cell depletion strategies. Collectively, these findings establish immunoglobulin heavy chain constant domains as promising targets for TCR-based cellular immunotherapy in MM and potentially other immunoglobulin-producing malignancies or autoantibody-mediated autoimmune diseases.
- 15 October 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (16) , 1998-2012
Immunoglobulin constant domains as targets for T-cell receptor–based treatment of multiple myeloma
Despite major progress with chimeric antigen receptor T-cell therapy, multiple myeloma (MM) remains largely incurable and most patients relapse. To broaden therapeutic options and overcome antigen escape, we explored T-cell receptor (TCR)–based targeting of intracellular antigens derived from immunoglobulin heavy chain constant domains. Using HLA class-I peptidomics, we identified 9 immunoglobulin G (IgG)– or IgA-derived peptides presented by common HLA alleles (HLA-A∗01:01, HLA-A∗02:01, HLA-A∗03:01, and HLA-B∗07:02). High-avidity T-cell clones recognizing 4 of these epitopes were isolated from HLA-mismatched healthy donors. The transfer of these immunoglobulin-specific TCRs into donor T cells conferred potent and selective recognition of IgG- or IgA-expressing MM cell lines, sparing antigen-negative cells. Safety profiling confirmed strict HLA-restricted specificity without cross-reactivity toward other HLA alleles, non–B-lineage tumor cell lines, or healthy tissues, except for the depletion of isotype-matched B cells. Immunoglobulin-TCR T cells efficiently lysed patient-derived MM cells ex vivo and eradicated established IgA- or IgG-expressing MM tumors in murine xenograft models. Mechanistic studies revealed that dendritic cells could cross-present immunoglobulin peptides at high serum concentrations, potentially enhancing T-cell activation in vivo. Importantly, subtype-specific depletion of B cells implies that immunoglobulin-TCR T-cell therapy could partly preserve humoral immunity, reducing the need for antibody replacement compared with pan–B-cell depletion strategies. Collectively, these findings establish immunoglobulin heavy chain constant domains as promising targets for TCR-based cellular immunotherapy in MM and potentially other immunoglobulin-producing malignancies or autoantibody-mediated autoimmune diseases.
- Open Access
- 3 September 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Chimeric HLA Antibody Receptor T Cells to Specifically Eliminate HLA-DQ–Specific B Cells
Key Points: HLA-DQ2/DQ7 chimeric HLA antibody receptor T cells, the first HLA class II chimeric HLA antibody receptor T cells, selectively eliminated cognate HLA-DQ–specific B cells in a dose-dependent manner. HLA-DQ chimeric HLA antibody receptor T cells efficiently depleted HLA-DQ–specific B cells with corresponding specificity in vivo . Chimeric HLA antibody receptor T-cell therapy expanded donor availability through targeted desensitization and represented a potential antigen-specific antibody-mediated rejection therapy. Background: Chimeric antigen receptor T-cell therapy has revolutionized the treatment of hematologic malignancies by effectively eliminating tumor cells. In the field of kidney transplantation, comparable cellular therapies are being explored to facilitate transplantation and prevent graft rejection. Chimeric HLA antibody receptor (CHAR) T cells are a promising therapy for eliminating HLA-specific B cells in sensitized patients and potentially ameliorating antibody-mediated rejection. We previously demonstrated that HLA class I CHAR T cells selectively eliminated HLA class I–specific B cells with high specificity. Since HLA sensitization is most often directed against HLA-DQ of the allograft, we developed HLA-DQ2 and HLA-DQ7 CHAR T cells to target B cells with corresponding HLA specificity. Methods: We designed viral vectors encoding HLA-DQ CHARs composed of HLA-DQA1*05:01 α chain with either HLA-DQB1*02:01 (HLA-DQ2) or HLA-DQB1*03:01 (HLA-DQ7) β chains, class II–associated invariant chain peptide, and intracellular 4-1BB costimulatory and CD3ζ signaling domains. Upon production of HLA-DQ CHAR T cells, we evaluated CHAR expression, cytotoxic activity, production of cytokines and cytotoxic mediators, and sensitivity to immunosuppressive drugs in in vitro models. We further assessed the cytotoxic activity of HLA-DQ CHAR T cells in an immunodeficient mouse model and in primary material from sensitized individuals. Results: CHAR-transduced Jurkat triple parameter reporter cells expressing reporter constructs for T-cell activation markers showed robust activation upon specific stimulation. Primary CD8 + T cells expressing HLA-DQ2 and HLA-DQ7 CHAR molecules specifically eliminated HLA-DQ2– or HLA-DQ7–specific B cells, respectively, and produced interferon gamma, soluble Fas ligand, perforin, and granzyme B. Maintenance immunosuppressive drug regimens initiated at the time of coincubation with target cells had limited effects on CHAR T-cell functionality. Finally, HLA-DQ CHAR T cells effectively eliminated HLA-DQ–specific B cells in an in vivo mouse model, as well as in primary material from sensitized individuals. Conclusions: HLA-DQ2 and HLA-DQ7 CHAR T cells, the first HLA class II CHAR T cells, selectively and effectively eliminated corresponding HLA-DQ–specific B cells in vitro , in vivo , and in primary material from sensitized individuals.
- 3 September 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Open AccessChimeric HLA Antibody Receptor T Cells to Specifically Eliminate HLA-DQ–Specific B Cells
Key Points: HLA-DQ2/DQ7 chimeric HLA antibody receptor T cells, the first HLA class II chimeric HLA antibody receptor T cells, selectively eliminated cognate HLA-DQ–specific B cells in a dose-dependent manner. HLA-DQ chimeric HLA antibody receptor T cells efficiently depleted HLA-DQ–specific B cells with corresponding specificity in vivo . Chimeric HLA antibody receptor T-cell therapy expanded donor availability through targeted desensitization and represented a potential antigen-specific antibody-mediated rejection therapy. Background: Chimeric antigen receptor T-cell therapy has revolutionized the treatment of hematologic malignancies by effectively eliminating tumor cells. In the field of kidney transplantation, comparable cellular therapies are being explored to facilitate transplantation and prevent graft rejection. Chimeric HLA antibody receptor (CHAR) T cells are a promising therapy for eliminating HLA-specific B cells in sensitized patients and potentially ameliorating antibody-mediated rejection. We previously demonstrated that HLA class I CHAR T cells selectively eliminated HLA class I–specific B cells with high specificity. Since HLA sensitization is most often directed against HLA-DQ of the allograft, we developed HLA-DQ2 and HLA-DQ7 CHAR T cells to target B cells with corresponding HLA specificity. Methods: We designed viral vectors encoding HLA-DQ CHARs composed of HLA-DQA1*05:01 α chain with either HLA-DQB1*02:01 (HLA-DQ2) or HLA-DQB1*03:01 (HLA-DQ7) β chains, class II–associated invariant chain peptide, and intracellular 4-1BB costimulatory and CD3ζ signaling domains. Upon production of HLA-DQ CHAR T cells, we evaluated CHAR expression, cytotoxic activity, production of cytokines and cytotoxic mediators, and sensitivity to immunosuppressive drugs in in vitro models. We further assessed the cytotoxic activity of HLA-DQ CHAR T cells in an immunodeficient mouse model and in primary material from sensitized individuals. Results: CHAR-transduced Jurkat triple parameter reporter cells expressing reporter constructs for T-cell activation markers showed robust activation upon specific stimulation. Primary CD8 + T cells expressing HLA-DQ2 and HLA-DQ7 CHAR molecules specifically eliminated HLA-DQ2– or HLA-DQ7–specific B cells, respectively, and produced interferon gamma, soluble Fas ligand, perforin, and granzyme B. Maintenance immunosuppressive drug regimens initiated at the time of coincubation with target cells had limited effects on CHAR T-cell functionality. Finally, HLA-DQ CHAR T cells effectively eliminated HLA-DQ–specific B cells in an in vivo mouse model, as well as in primary material from sensitized individuals. Conclusions: HLA-DQ2 and HLA-DQ7 CHAR T cells, the first HLA class II CHAR T cells, selectively and effectively eliminated corresponding HLA-DQ–specific B cells in vitro , in vivo , and in primary material from sensitized individuals.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Movie 1 - TEM assay MOCK transduced endothelial cells and CD8 T cells from VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation
Movie of a transendothelial migration assay using MOCK transduced endothelial cells and CD8 T cells that were derived from healthy PBMCs. Total duration of the movie is 20 minutes. Each datapoint in figure 5 and supplementary figures 7 and 8 is derived from the quantification of migration of a single video.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie 1 - TEM assay MOCK transduced endothelial cells and CD8 T cells from VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation
Movie of a transendothelial migration assay using MOCK transduced endothelial cells and CD8 T cells that were derived from healthy PBMCs. Total duration of the movie is 20 minutes. Each datapoint in figure 5 and supplementary figures 7 and 8 is derived from the quantification of migration of a single video.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures and Tables from VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation
Supplementary Figures and Tables
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures and Tables from VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation
Supplementary Figures and Tables
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Movie 2 - TEM assay VISTA transduced endothelial cells and CD8 T cells from VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation
Movie of a transendothelial migration assay using VISTA transduced endothelial cells and total CD8 T cells that were derived from healthy PBMCs. Total duration of the movie is 20 minutes. Each datapoint in figure 5 and supplementary figures 7 and 8 is derived from the quantification of migration of a single video.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie 2 - TEM assay VISTA transduced endothelial cells and CD8 T cells from VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation
Movie of a transendothelial migration assay using VISTA transduced endothelial cells and total CD8 T cells that were derived from healthy PBMCs. Total duration of the movie is 20 minutes. Each datapoint in figure 5 and supplementary figures 7 and 8 is derived from the quantification of migration of a single video.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Data from VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation
Cancers evade T-cell immunity by several mechanisms such as secretion of anti-inflammatory cytokines, down regulation of antigen presentation machinery, upregulation of immune checkpoint molecules, and exclusion of T cells from tumor tissues. The distribution and function of immune checkpoint molecules on tumor cells and tumor-infiltrating leukocytes is well established, but less is known about their impact on intratumoral endothelial cells. Here, we demonstrated that V-domain Ig suppressor of T-cell activation (VISTA), a PD-L1 homolog, was highly expressed on endothelial cells in synovial sarcoma, subsets of different carcinomas, and immune-privileged tissues. We created an ex vivo model of the human vasculature and demonstrated that expression of VISTA on endothelial cells selectively prevented T-cell transmigration over endothelial layers under physiologic flow conditions, whereas it does not affect migration of other immune cell types. Furthermore, endothelial VISTA correlated with reduced infiltration of T cells and poor prognosis in metastatic synovial sarcoma. In endothelial cells, we detected VISTA on the plasma membrane and in recycling endosomes, and its expression was upregulated by cancer cell–secreted factors in a VEGF-A–dependent manner. Our study reveals that endothelial VISTA is upregulated by cancer-secreted factors and that it regulates T-cell accessibility to cancer and healthy tissues. This newly identified mechanism should be considered when using immunotherapeutic approaches aimed at unleashing T cell–mediated cancer immunity.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation
Cancers evade T-cell immunity by several mechanisms such as secretion of anti-inflammatory cytokines, down regulation of antigen presentation machinery, upregulation of immune checkpoint molecules, and exclusion of T cells from tumor tissues. The distribution and function of immune checkpoint molecules on tumor cells and tumor-infiltrating leukocytes is well established, but less is known about their impact on intratumoral endothelial cells. Here, we demonstrated that V-domain Ig suppressor of T-cell activation (VISTA), a PD-L1 homolog, was highly expressed on endothelial cells in synovial sarcoma, subsets of different carcinomas, and immune-privileged tissues. We created an ex vivo model of the human vasculature and demonstrated that expression of VISTA on endothelial cells selectively prevented T-cell transmigration over endothelial layers under physiologic flow conditions, whereas it does not affect migration of other immune cell types. Furthermore, endothelial VISTA correlated with reduced infiltration of T cells and poor prognosis in metastatic synovial sarcoma. In endothelial cells, we detected VISTA on the plasma membrane and in recycling endosomes, and its expression was upregulated by cancer cell–secreted factors in a VEGF-A–dependent manner. Our study reveals that endothelial VISTA is upregulated by cancer-secreted factors and that it regulates T-cell accessibility to cancer and healthy tissues. This newly identified mechanism should be considered when using immunotherapeutic approaches aimed at unleashing T cell–mediated cancer immunity.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Supplementary Table S3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Supplementary Table S3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 8 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Boxplots depicting (A) CDH23 and (B) LOXHD1 expression in various tumor types (TCGA data n=30) and healthy tissue types (TCGA data n=30 and GTEx data n=5-20). Red, green and white boxplots represent tumor types (TCGA data), healthy tissues (TCGA data), and healthy tissues (GTEx), respectively. Boxplots extend from first to third quartile, the horizontal line represent the median expression value. The whiskers represent the minimum and maximum expression value (1.5 IQR from the first and third quartile). Outliers are defined as being 1.5*IQR or more above the third or below the first quartile, respectively. Y-axis abbreviations are described in supplemental table 1. (FC: fold change, GTEx: genotype-tissue expression, IQR: interquartile range, log2-CPM: log2-transformed counts per million, TCGA: The cancer genome atlas)
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 8 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Boxplots depicting (A) CDH23 and (B) LOXHD1 expression in various tumor types (TCGA data n=30) and healthy tissue types (TCGA data n=30 and GTEx data n=5-20). Red, green and white boxplots represent tumor types (TCGA data), healthy tissues (TCGA data), and healthy tissues (GTEx), respectively. Boxplots extend from first to third quartile, the horizontal line represent the median expression value. The whiskers represent the minimum and maximum expression value (1.5 IQR from the first and third quartile). Outliers are defined as being 1.5*IQR or more above the third or below the first quartile, respectively. Y-axis abbreviations are described in supplemental table 1. (FC: fold change, GTEx: genotype-tissue expression, IQR: interquartile range, log2-CPM: log2-transformed counts per million, TCGA: The cancer genome atlas)
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Supplementary Table S1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Supplementary Table S1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer